An open-label, phase II study of weekly nab-paclitaxel as first-line therapy for patients (pts) with metastatic breast cancer (MBC): Safety update.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 1127-1127 ◽  
Author(s):  
C. B. Brezden ◽  
G. Cantin ◽  
J. Younus ◽  
L. C. Panasci ◽  
P. Klimo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Metastatic Breast ◽  
First Line ◽  
Open Label ◽  
First Line Therapy ◽  
Line Therapy ◽  
Open Label Phase

scholarly journals First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: A phase II study

BMC Cancer ◽  
2005 ◽  
Vol 5 (1) ◽  
Author(s):  
Djelila Allouache ◽  
Sulochana R Gawande ◽  
Michele Tubiana-Hulin ◽  
Nicole Tubiana-Mathieu ◽  
Sophie Piperno-Neumann ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Metastatic Breast ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy ◽  
Locally Recurrent

scholarly journals Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer

2006 ◽  
Vol 94 (11) ◽  
pp. 1604-1609 ◽  
Author(s):  
F Ciardiello ◽  
T Troiani ◽  
F Caputo ◽  
M De Laurentiis ◽  
G Tortora ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Metastatic Breast ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy
Sign in / Sign up

Export Citation Format

Share Document